WO2022088400A1 - Procédé de fabrication de variation de structure chromosomique - Google Patents
Procédé de fabrication de variation de structure chromosomique Download PDFInfo
- Publication number
- WO2022088400A1 WO2022088400A1 PCT/CN2020/134673 CN2020134673W WO2022088400A1 WO 2022088400 A1 WO2022088400 A1 WO 2022088400A1 CN 2020134673 W CN2020134673 W CN 2020134673W WO 2022088400 A1 WO2022088400 A1 WO 2022088400A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- cells
- preset
- protein kinase
- expression vector
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 210000001726 chromosome structure Anatomy 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract description 117
- 210000000349 chromosome Anatomy 0.000 claims abstract description 69
- 229940122466 DNA-dependent protein kinase inhibitor Drugs 0.000 claims abstract description 42
- 108020004414 DNA Proteins 0.000 claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 29
- 108091033409 CRISPR Proteins 0.000 claims abstract description 27
- 208000037088 Chromosome Breakage Diseases 0.000 claims abstract description 22
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 9
- 239000013604 expression vector Substances 0.000 claims description 53
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 33
- 230000002759 chromosomal effect Effects 0.000 claims description 33
- 230000005945 translocation Effects 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000003752 polymerase chain reaction Methods 0.000 claims description 9
- 238000004520 electroporation Methods 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 238000001962 electrophoresis Methods 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 abstract description 10
- 230000005971 DNA damage repair Effects 0.000 abstract description 7
- 230000005886 chromosome breakage Effects 0.000 abstract description 7
- 238000002744 homologous recombination Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 7
- 230000037361 pathway Effects 0.000 abstract description 7
- 230000006801 homologous recombination Effects 0.000 abstract description 6
- 102000001253 Protein Kinase Human genes 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 108060006633 protein kinase Proteins 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 abstract 2
- 208000034951 Genetic Translocation Diseases 0.000 description 37
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 25
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 25
- 238000010276 construction Methods 0.000 description 12
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000003909 protein kinase inhibitor Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 210000003292 kidney cell Anatomy 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000010459 TALEN Methods 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 101150023956 ALK gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 3
- 101150084041 WT1 gene Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000007035 DNA breakage Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090000740 RNA-binding protein EWS Proteins 0.000 description 2
- 102000004229 RNA-binding protein EWS Human genes 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003426 interchromosomal effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108050008316 DNA endonuclease RBBP8 Proteins 0.000 description 1
- 102100039524 DNA endonuclease RBBP8 Human genes 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100027828 DNA repair protein XRCC4 Human genes 0.000 description 1
- 101150112524 EWSR1 gene Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000927810 Homo sapiens DNA ligase 4 Proteins 0.000 description 1
- 101000649315 Homo sapiens DNA repair protein XRCC4 Proteins 0.000 description 1
- 101100172782 Homo sapiens EWSR1 gene Proteins 0.000 description 1
- 101000735456 Homo sapiens Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 description 1
- 108700020467 WT1 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Definitions
- the present application belongs to the technical field of gene editing, and specifically relates to a method for producing chromosome structural variation.
- Chromosomal structural variation is a kind of chromosomal variation, which is the result of the combined action of internal and external factors.
- the external factors include various rays, chemical agents, and drastic changes in temperature
- the internal factors include metabolic disorders and aging in organisms.
- the main types are deletion, duplication, inversion and translocation.
- chromosomal translocation is the change of the chromosomal location segment, including the location segment change within a single chromosome and the location segment change between chromosomes.
- Chromosomal translocations can be further divided into non-reciprocal translocations and reciprocal translocations. The occurrence of chromosomal translocation requires two conditions, one is the presence of DNA breaks on both chromosomes at the same time; the other is the DNA damage repair mechanism in vivo to reconnect the DNA ends between different chromosomes.
- the present application provides a method for producing chromosomal structural variation, so as to solve the technical problem of low efficiency of chromosomal structural variation.
- a technical solution adopted in the present application is: a method for producing a chromosomal translocation, comprising: forming a preset chromosomal break; treating the cell with a DNA-dependent protein kinase inhibitor to obtain a structurally mutated Preset chromosomes.
- the treating the cells with a DNA-dependent protein kinase inhibitor includes: treating the cells with a DNA-dependent protein kinase inhibitor at a first preset concentration for a first preset time; stopping all The effect of the DNA-dependent protein kinase inhibitor on the cells is further cultured for a second preset time, and the cells are collected.
- the treating the cells with a DNA-dependent protein kinase inhibitor includes: culturing the cells with a medium containing a DNA-dependent protein kinase inhibitor M3814 for 10h-20h, the DNA-dependent protein kinase inhibitor M3814
- the first preset concentration of protein kinase inhibitor M3814 is 100nM-1 ⁇ M; replace the medium without the DNA-dependent protein kinase inhibitor M3814 to culture the cells for 24h-32h, and collect the cells;
- the cells were cultured for 10h-20h in the medium of DNA-dependent protein kinase inhibitor KU57788, and the first preset concentration of the DNA-dependent protein kinase inhibitor KU57788 was 1 ⁇ M-10 ⁇ M; it was changed to not contain the DNA-dependent protein kinase
- the cells were cultured for 24h-32h in medium with kinase inhibitor M3814, and the cells were harvested.
- the forming a predetermined chromosome break comprises: constructing a CRISPR system for the predetermined chromosome break; and introducing the CRISPR system into a cell.
- the construction of a CRISPR system for preset chromosome breakage includes: synthesizing a pCS2-Cas9 expression vector using a preset primer sequence; vector.
- the introduction of the CRISPR system into a cell includes: using liposomes to mix the pCS2-Cas9 expression vector and the sgRNA expression vector to transfect the cells for a third preset time, so that the cells are transfected for a third preset time.
- the pCS2-Cas9 expression vector and the sgRNA expression vector are introduced into the cells.
- the construction of a CRISPR system for presetting chromosome breakage further includes: sequencing the pCS2-Cas9 expression vector and the sgRNA expression vector to verify the pCS2-Cas9 expression vector, and using the pCS2-Cas9- The cells were transfected with the Cas9 expression vector and the sgRNA expression vector.
- the construction of a CRISPR system for preset chromosome breakage includes: synthesizing a forward primer and a reverse primer of the target template DNA; using the forward primer and reverse primer of the target template DNA, through Amplify the target template DNA by polymerase chain reaction; use RNA transcription reagent to transcribe the target template DNA, and purify to obtain sgRNA; obtain the Cas9 wild-type protein expression vector, and transform the strain to induce the Cas9 wild-type protein expression vector Expressed in the strain; harvested and disrupted the strain, harvested and purified the Cas9 protein.
- the introduction of the CRISPR system into a cell includes: mixing and incubating the sgRNA and the Cas9 protein at room temperature to obtain a nucleic acid-protein complex; mixing the nucleic acid-protein complex with the The electroporation solution of the cells is mixed, and the cells are electroporated to introduce the nucleic acid-protein complex into the cells.
- the method includes: synthesizing a forward primer and a reverse primer of the structurally mutated preset chromosomal gene; using the forward primer and the reverse primer to perform polymerase chain reaction , to amplify the preset chromosomal gene after the structural variation; observe the translocation effect of the preset chromosome by electrophoresis analysis; the sequence of the forward primer is selected from: SEQ ID NO1:5'-CAGTTGCTTGGTTCCCAGTT-3 '; and SEQ ID NO2:5'-GGGGAGAGGAAATCTTGCTG-3'; or as: SEQ ID NO3:5'-GTTGCTCACTTCTCTTGGGGCT-3'; the sequence of the reverse primer is selected from as: SEQ ID NO4:5'-AGGAATTGGCCTGCCTTAGT-3 '; and SEQ ID NO5:5'-GCAGCTTCAGTGCAATCACA-3'; or as: SEQ ID NO6:5'-TCAAGAAAT
- DNA-PK is a key protein kinase in the non-homologous recombination end repair (NHEJ) pathway in DNA damage repair.
- NHEJ non-homologous recombination end repair
- the DNA-PK activity is temporarily inhibited by using a DNA-dependent protein kinase inhibitor, so that the generated DNA ends cannot be rapidly connected by the in vivo DNA damage repair NHEJ system, thus increasing the amount of interchromosomal DNA.
- the chance of breaking end contacts, thereby increasing the probability of chromosomal structural variation is used in the construction of chromosomal structural variation disease models.
- FIG. 1 is a schematic flow chart of an embodiment of a method for producing chromosomal structural variation of the present application
- FIG. 2 is a schematic diagram of a chromosomal translocation in a specific embodiment of the method for producing chromosomal structural variation of the present application
- FIG. 3 is a schematic diagram of the effect of detecting translocations in specific embodiment 1 and specific embodiment 2 in the method for producing chromosomal structural variation of the present application;
- FIG. 4 is a schematic diagram showing the effect of detecting translocations in specific embodiment 3 and specific embodiment 4 in the method for producing chromosomal structural variation of the present application.
- ZFN zinc finger nucleases
- TALEN transcription activator-like effector nuclease technology
- CRISPR clustered regularly interspaced short palindromic repeats
- the applicant's research has found that DNA damage can be repaired in various ways.
- the homologous recombination repair pathway depends on the repair template, and the DNA damage site is repaired according to the sequence of the repair template; non-homologous recombination DNA end joining (NHEJ) does not depend on the repair template. , the broken DNA ends can be rejoined.
- Non-homologous recombination DNA end joining is also divided into two pathways, one is the canonical pathway (canonical NHEJ), which depends on XRCC4 and LIG4 and PARP3; Source end joining (MMHJ), dependent on CtIP and PARP1.
- DNA-dependent protein kinase is a key protein kinase in the non-homologous recombination end repair (NHEJ) pathway in DNA damage repair.
- NHEJ non-homologous recombination end repair
- Inhibition of DNA-PK generally enhances the effect of radiation on cancer cells because inhibition of DNA-PK reduces the ability of cancer cells to repair the genome, thereby activating apoptotic pathways.
- Inhibition of DNA-PK can reduce the frequency of NHEJ, which can be used to increase the efficiency of homologous recombination. Therefore, the present application achieves an increase in the probability of chromosomal structural variation by inhibiting DNA-PK.
- FIG. 1 is a schematic flowchart of an embodiment of a method for producing a chromosomal structural variation of the present application.
- the application provides a method for making chromosome structural variation, comprising the following steps:
- ZFNs zinc finger nucleases
- TALENs transcription activator-like effector nucleases
- CRISPR clustered regularly interspaced short palindromic repeats
- the formation of preset chromosomal breaks includes:
- Construction of a CRISPR system for pre-set chromosomal breaks can be accomplished in at least two ways:
- the first method A-1 is a first method A-1:
- the primers in Table 1 were synthesized and PCR amplified with Q5 high-fidelity enzyme, and the pCS2-Cas9 expression vector was constructed by seamless cloning technology.
- the expression vector In order to ensure the successful construction of the expression vector, it can be verified by sequencing whether the sequences of the pCS2-Cas9 expression vector and sgRNA expression vector are the same as the preset ones.
- the second method A-2 is a first method A-2:
- the target template DNA is transcribed using RNA transcription reagents and purified to obtain sgRNA.
- the strains were collected and disrupted, and the Cas9 protein was collected and purified.
- a CRISPR system for preset chromosome breakage can be constructed by both methods. Of course, in other embodiments, other methods can also be used to construct the CRISPR system.
- the introduction of the CRISPR system into cells can also be achieved by at least the following two methods of B-1 and B-2:
- the first method B-1 needs to be correspondingly used to introduce the CRISPR system into the cell:
- the first method B-1 is a first method B-1:
- the pCS2-Cas9 expression vector and the sgRNA expression vector were mixed with liposomes to transfect the cells for a third preset time, so as to introduce the pCS2-Cas9 expression vector and the sgRNA expression vector into the cells.
- step S101 If the second method A-2 in step S101 is used to construct the CRISPR system for preset chromosome breakage, the second method B-2 needs to be used to introduce the CRISPR system into the cell:
- RNP nucleic acid protein complex
- the nucleic acid protein complex is mixed with the electroporation solution containing the cells, and the cells are electroporated to introduce the nucleic acid protein complex into the cells.
- the CRISPR system can be introduced into cells to target preset chromosomes, thereby causing DNA double-strand breaks.
- S12 Treatment of cells with DNA-dependent protein kinase inhibitors to obtain pre-set chromosomes after structural variation.
- DNA-PK DNA-dependent protein kinase
- the effect of the DNA-dependent protein kinase inhibitor on the cells is stopped, the culture is continued for a second preset time, the cells are collected, and the preset chromosomes in the cells undergo structural variation.
- the DNA-dependent protein kinase inhibitor can be selected from DNA-dependent protein kinase inhibitor M3814 or DNA-dependent protein kinase inhibitor KU57788, and in other embodiments, other DNA-dependent protein kinase inhibitors can also be selected.
- the first preset time, the second preset time, etc. can be specifically adjusted according to the type of DNA-dependent protein kinase (DNA-PK) inhibitor and the first preset concentration.
- DNA-PK DNA-dependent protein kinase
- the DNA-PK activity is temporarily inhibited by using a DNA-dependent protein kinase inhibitor, so that the generated DNA ends cannot be rapidly connected by the in vivo DNA damage repair NHEJ system, thus increasing the amount of interchromosomal DNA.
- the chance of breaking end contacts, thereby increasing the probability of chromosomal structural variation is used in the construction of chromosomal structural variation disease models.
- Example 1 A-1 combined with B-1 method was used to construct a CRISPR system for preset chromosomal translocation, and introduce it into cells, specifically:
- the pCS2-Cas9 expression vector was synthesized using preset primer sequences.
- the preset primer sequences are shown in Table 1 above.
- the primers in Table 1 were synthesized and PCR amplified with Q5 high-fidelity enzyme, and the pCS2-Cas9 expression vector was constructed by seamless cloning technology.
- the preset chromosomes are chromosome 5 of the human genome and chromosome 2 of the human genome, and sgRNA expression vectors related to the translocation sites of the preset chromosomes are synthesized respectively.
- the specific sgRNA targeting sites related to the translocation sites of the preset chromosomes are as follows :
- NPM is located on chromosome 5 of the human genome:
- NPM 1-sg F 5'-ACCGTGAACCCAGTAGCAGTTCG-3';
- NPM1-sg R 5'-AAACCGAACTGCTACTGGGTTCAC-3'.
- ALK is located on chromosome 2 of the human genome:
- ALK-sg F 5'-ACCGTCGGTCCATTGCATAGAGG-3';
- ALK-sg R 5'-AAACCCTCTATGCAATGGACCGAC-3'.
- the same amount of F and R oligonucleotides were mixed, denatured at high temperature, annealed to form short double-stranded DNA, and the short double-stranded DNA formed by annealing was ligated to the restriction endonuclease Bsa I-treated pGL3- On the U6-sgRNA vector, the sgRNA expression vector related to the translocation site of the preset chromosome is formed.
- the pCS2-Cas9 expression vector and sgRNA expression vector were verified by sequencing.
- the transfection time can be adjusted in real time according to the actual transfection conditions and transfection progress.
- the cells were treated with DNA-dependent protein kinase inhibitor M3814 at a first preset concentration of 500nM for a first preset time of 18h;
- DNA-dependent protein kinase inhibitor M3814 The effect of DNA-dependent protein kinase inhibitor M3814 on the cells was stopped, and the cells were cultured for a second preset time of 30 h by replacing with a medium without DNA-dependent protein kinase inhibitor M3814, and the cells were collected.
- the parameters are selected as above.
- the first preset concentration is 100nM-1 ⁇ M, such as 100nM, 500nM or 1 ⁇ M, etc.
- the first preset concentration should not be too high, which will cause toxicity to cells.
- the first preset time is 10h-20h, for example, 10h, 14h, 18h, or 20h.
- the second preset time is 24h-32h, for example, 24h, 28h, 30h, or 32h.
- the NPM-ALK chromosomal translocation utilizes two sets of primers, the first set: NPM-ALK-F1 (SEQ ID NO1): 5'-CAGTTGCTTGGTTCCCAGTT-3' and NPM-ALK-R1 (SEQ ID NO4): 5'-AGGAATTGGCCTGCCTTAGT- 3'; the second group: NPM-ALK-F2 (SEQ ID NO2): 5'-GGGGAGAGGAAATCTTGCTG-3' and NPM-ALK-R2 (SEQ ID NO5): 5'-GCAGCTTCAGTGCAATCACA-3' were detected by nested PCR.
- nested PCR The advantage of nested PCR is that if the first amplification produces an erroneous fragment, the probability of primer pairing and amplification on the erroneous fragment the second time is extremely low. Therefore, the amplification of nested PCR is very specific and the detection accuracy is high.
- Example 2 the A-1 combined with B-1 method was also used to construct a CRISPR system for preset chromosomal translocation and introduce it into cells.
- Example 2 The method for constructing the CRISPR system for preset chromosomal translocation in Example 2 is basically the same as that in Example 1, which will not be repeated here, and the differences are:
- the preset chromosomes are human genome chromosome 22 and human genome chromosome 11, and the specific sgRNA targeting sites related to the translocation sites of the preset chromosomes are as follows:
- EWSR1 is located on chromosome 22 of the human genome:
- EWSR1-sg F 5'-ACCGGGGCATCCAAGATGTTAGC-3';
- EWSR1-sg R 5'-AAACGCTAACATCTTGGATGCCCC-3'.
- WT1 is located on chromosome 11 of the human genome:
- WT1-sg F 5'-ACCGGGCTGAGCCCTTTATGTGA-3';
- WT1-sg R 5'-AAACTCACATAAAGGGCTCAGCCC-3'.
- the cells were treated with DNA-dependent protein kinase inhibitor M3814 at a first preset concentration of 500nM for a first preset time of 18h;
- DNA-dependent protein kinase inhibitor M3814 The effect of DNA-dependent protein kinase inhibitor M3814 on cells was stopped, and the cells were cultured for a second preset time of 30 h by replacing with a medium without DNA-dependent protein kinase inhibitor M3814, and cells were collected.
- the parameters are selected as above.
- the first preset concentration is 100nM-1 ⁇ M, such as 100nM, 500nM or 1 ⁇ M, etc.
- the first preset concentration should not be too high, which will cause toxicity to cells.
- the first preset time is 10h-20h, for example, 10h, 14h, 18h, or 20h.
- the second preset time is 24h-32h, for example, 24h, 28h, 30h, or 32h.
- EWSR-WT translocation was detected by PCR using primers as follows: EWSR-WT-F (SEQ ID NO 3): 5'-GTTGCTCACTTCTCTTGGGGCT-3' and EWSR-WT-R (SEQ ID NO 6): 5'-TCAAGAAATGAAAACAGAGCCAGGT-3'.
- the chromosomal translocation effects of Examples 1 and 2 are shown in FIG. 2 .
- the NPM and ALK gene loci are located on chromosome 5 and chromosome 2 of the human genome, respectively, and the arrows below or above the gene name indicate the direction of transcription of the gene.
- breaks are formed in the two chromosomes under CRISPR cleavage.
- an NPM-ALK translocation is formed, which can be amplified by the primers indicated by the black arrows shown on the right. target fragment.
- EWSR1 and WT1 are located on chromosome 22 and chromosome 11 of the human genome, respectively.
- CRISPR targets these two chromosomes to cut and reconnect to form a WT1-EWSR1 chromosomal translocation.
- Example 1 and Example 2 The specific detection results of Example 1 and Example 2 are shown in FIG. 3 .
- the DNA-PK inhibitor M3814 significantly increased NPM-ALK and WT1-EWSR1 chromosomal translocations in human embryonic kidney cells.
- the CRISPR system targeting NPM and ALK gene loci, or the CRISPR system targeting WT1 and EWSR1 gene loci were introduced into human embryonic kidney 293T cells, and then the cells were treated with DNA-PK inhibitor M3814, and the cells were collected to detect chromosomal translocation. bit effect.
- WT represents cells without the introduction of the CRISPR system, and no chromosomal translocations were detected. Chromosomal translocations were detected in all cells introduced with the CRISPR system, and significantly stronger chromosomal translocation signals were found in M3814-treated cells.
- Actin beta is an internal reference gene.
- the DNA-PK inhibitor can be used to temporarily inhibit DNA-PK activity, which can significantly improve the efficiency of chromosomal translocation.
- Example 3 A-2 combined with B-2 method was used to construct a CRISPR system for preset chromosomal translocation and introduce it into cells, specifically:
- the default chromosomes are human genome chromosome 5 and human genome chromosome 2.
- the target template DNA is used to transcribe the sgRNA.
- the forward primer and reverse primer of the target template DNA are as follows:
- the preset translocation site NPM is located on chromosome 5 of the human genome:
- the preset translocation site ALK is located on chromosome 2 of the human genome:
- the target template DNA is amplified by polymerase chain reaction according to the conditions provided by the kit.
- the kit can be selected from the Invitrogen precision gRNA synthesis kit (Cat. No. A29377).
- RNA transcription reagent provided by the kit to transcribe the target template DNA to obtain sgRNA, and purify to obtain sgRNA.
- the Cas9 wild-type protein expression vector was purchased from Addgene (Cat. No. 62374)), transform the strain, and induce the Cas9 wild-type protein expression vector to express in the strain overnight at 20°C and 0.5 mM IPTG.
- Bacterial cells were collected the next day, strains were sonicated, and Cas9 protein was affinity-purified with Ni-NTA, followed by ion-exchange purification of Cas9 protein on an AKTA instrument.
- sgRNA and 1.6 ⁇ g Cas9 protein were mixed and incubated at room temperature for 10 minutes to obtain nucleic acid-protein complexes; then mixed with 20 ⁇ L of electroporation solution containing 3.0 ⁇ 10 5 cells, transferred to a 20 ⁇ L electroporation tube, and passed on an electroporator 380V, 30ms parameters electroporation cells, so as to introduce the nucleic acid protein complex into the cells, the cells are human embryonic kidney cells.
- DNA-dependent protein kinase inhibitor M3814 The effect of DNA-dependent protein kinase inhibitor M3814 on the cells was stopped, and the culture medium without DNA-dependent protein kinase inhibitor M3814 was replaced to culture the cells for a second preset time of 32 h, and then the cells were collected.
- the parameters are selected as above.
- the first preset concentration is 100nM-1 ⁇ M, such as 100nM, 500nM or 1 ⁇ M, etc.
- the first preset concentration should not be too high, which will cause toxicity to cells.
- the first preset time is 10h-20h, for example, 10h, 14h, 18h, or 20h.
- the second preset time is 24h-32h, for example, 24h, 28h, 30h, or 32h.
- the NPM-ALK chromosomal translocation utilizes two sets of primers, the first set: NPM-ALK-F1 (SEQ ID NO1): 5'-CAGTTGCTTGGTTCCCAGTT-3' and NPM-ALK-R1 (SEQ ID NO4): 5'-AGGAATTGGCCTGCCTTAGT- 3'; the second group: NPM-ALK-F2 (SEQ ID NO2): 5'-GGGGAGAGGAAATCTTGCTG-3' and NPM-ALK-R2 (SEQ ID NO5): 5'-GCAGCTTCAGTGCAATCACA-3' were detected by nested PCR.
- nested PCR The advantage of nested PCR is that if the first amplification produces an erroneous fragment, the probability of primer pairing and amplification on the erroneous fragment the second time is extremely low. Therefore, the amplification of nested PCR is very specific and the detection accuracy is high.
- Example 4 A-2 combined with B-2 method was used to construct a CRISPR system for preset chromosomal translocation and introduce it into cells, specifically:
- the preset chromosomes are human genome chromosome 5 and human genome chromosome 2, and the preset translocation sites are NPM and ALK.
- the method of constructing a CRISPR system for preset chromosomal translocation is the same as that in Example 3, and will not be repeated here. .
- the method of introducing the CRISPR system into cells is the same as that in Example 3, and will not be repeated here.
- the effect of the DNA-dependent protein kinase inhibitor KU57788 on the cells was stopped, and the cells were cultured for a second preset time of 30 h by replacing the medium without the DNA-dependent protein kinase inhibitor KU57788, and the cells were collected.
- the parameters are selected as above.
- the first preset concentration is 1 ⁇ M-10 ⁇ M, such as 1 ⁇ M, 5 ⁇ M or 10 ⁇ M, etc.
- the first preset concentration should not be too high, which will cause toxicity to cells.
- the first preset time is 10h-20h, for example, 10h, 14h, 16h, 18h, or 20h.
- the second preset time is 24h-32h, for example, 24h, 28h, 30h, or 32h.
- the method for detecting the translocation effect of the preset chromosome is the same as that in Embodiment 3, and will not be repeated here.
- Example 3 and Example 4 The chromosomal translocation effect of Example 3 and Example 4 is shown in FIG. 2 .
- the NPM and ALK gene loci are located on chromosome 5 and chromosome 2 of the human genome, respectively, and the arrows below or above the gene name indicate the direction of transcription of the gene.
- breaks are formed in the two chromosomes under CRISPR cleavage.
- an NPM-ALK translocation is formed, which can be amplified by the primers indicated by the black arrows shown on the right. target fragment.
- Example 3 and Example 4 The specific detection results of Example 3 and Example 4 are shown in Figure 4.
- the CRISPR system introduced human embryonic kidney cells in the form of nucleic acid protein complex RNP, they were treated with DNA-PK inhibitors M3814 (500nM) and KU57788 (10uM) for 16 48 hours after the introduction of the CRISPR system, the cells were collected to detect the effect of chromosomal translocation.
- WT represents untreated human embryonic kidney cells without any chromosomal translocations. Both DNA-PK inhibitors can significantly enhance the CRISPR-induced chromosomal translocation effect.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011205066.6A CN112481297A (zh) | 2020-11-02 | 2020-11-02 | 一种制造染色体结构变异的方法 |
CN202011205066.6 | 2020-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022088400A1 true WO2022088400A1 (fr) | 2022-05-05 |
Family
ID=74926403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/134673 WO2022088400A1 (fr) | 2020-11-02 | 2020-12-08 | Procédé de fabrication de variation de structure chromosomique |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112481297A (fr) |
WO (1) | WO2022088400A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115948477A (zh) * | 2022-07-20 | 2023-04-11 | 东北农业大学 | 一种提高CRISPR/Cas9的同源重组修复效率的诱导剂、方法以及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105543223A (zh) * | 2015-12-25 | 2016-05-04 | 华侨大学 | 一种基于miRNA/shRNA转录加工机制转录sgRNA的方法 |
WO2016081923A2 (fr) * | 2014-11-21 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Procédés et compositions pour modification génétique ciblée utilisant des arn guides appariés |
CN106399367A (zh) * | 2016-08-31 | 2017-02-15 | 深圳市卫光生物制品股份有限公司 | 提高crispr介导的同源重组效率的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3802826A1 (fr) * | 2018-05-24 | 2021-04-14 | CRISPR Therapeutics AG | Procédés et compositions pour la délétion de gène efficace |
-
2020
- 2020-11-02 CN CN202011205066.6A patent/CN112481297A/zh active Pending
- 2020-12-08 WO PCT/CN2020/134673 patent/WO2022088400A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016081923A2 (fr) * | 2014-11-21 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Procédés et compositions pour modification génétique ciblée utilisant des arn guides appariés |
CN105543223A (zh) * | 2015-12-25 | 2016-05-04 | 华侨大学 | 一种基于miRNA/shRNA转录加工机制转录sgRNA的方法 |
CN106399367A (zh) * | 2016-08-31 | 2017-02-15 | 深圳市卫光生物制品股份有限公司 | 提高crispr介导的同源重组效率的方法 |
Non-Patent Citations (3)
Title |
---|
CARR MICHAEL I., ZIMMERMANN ASTRID, CHIU LI-YA, ZENKE FRANK T., BLAUKAT ANDREE, VASSILEV LYUBOMIR T.: "DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia", FRONTIERS IN ONCOLOGY, vol. 10, 1 January 2020 (2020-01-01), pages 127, XP055926104, DOI: 10.3389/fonc.2020.00127 * |
POVIRK LAWRENCE F., ZHOU RUI-ZHE, RAMSDEN DALE A., LEES-MILLER SUSAN P., VALERIE KRISTOFFER: "Phosphorylation in the serine/threonine 2609–2647 cluster promotes but is not essential for DNA-dependent protein kinase-mediated nonhomologous end joining in human whole-cell extracts", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 35, no. 12, 1 June 2007 (2007-06-01), GB , pages 3869 - 3878, XP055926099, ISSN: 0305-1048, DOI: 10.1093/nar/gkm339 * |
WISE HANNAH C., IYER GOPAKUMAR V., MOORE KATHLEEN, TEMKIN SARAH M., GORDON SARAH, AGHAJANIAN CAROL, GRISHAM RACHEL N.: "Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models", SCIENTIFIC REPORTS, vol. 9, no. 1, 1 December 2019 (2019-12-01), pages 18882, XP055926101, DOI: 10.1038/s41598-019-54796-6 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115948477A (zh) * | 2022-07-20 | 2023-04-11 | 东北农业大学 | 一种提高CRISPR/Cas9的同源重组修复效率的诱导剂、方法以及应用 |
CN115948477B (zh) * | 2022-07-20 | 2024-05-28 | 东北农业大学 | 一种提高CRISPR/Cas9的同源重组修复效率的诱导剂、方法以及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112481297A (zh) | 2021-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106222177B (zh) | 一种靶向人STAT6的CRISPR-Cas9系统及其用于治疗过敏性疾病的应用 | |
JP2024112895A (ja) | 変更されたPAM特異性を有する遺伝子操作されたCRISPR-Cas9ヌクレアーゼ | |
AU2021339819A1 (en) | Base editing enzymes | |
US20230212612A1 (en) | Genome editing system and method | |
Jones 3rd et al. | In vivo translational start site selection on leaderless mRNA transcribed from the Streptomyces fradiae aph gene | |
WO2022088400A1 (fr) | Procédé de fabrication de variation de structure chromosomique | |
EP4428233A9 (fr) | Nouveau système d'édition génomique fondé sur la nucléase c2c9 et son application | |
WO2023206871A1 (fr) | Système crispr/spcas12f1 optimisé, arn guide modifié et son utilisation | |
US20240229012A9 (en) | Site-specific genome modification technology | |
EP4217499A1 (fr) | Systèmes et procédés de transposition de séquences nucléotidiques cargo | |
CN108998406B (zh) | 一种人类原代培养细胞基因组编辑、定点基因敲入方法 | |
CN113549650B (zh) | 一种CRISPR-SaCas9基因编辑系统及其应用 | |
WO2022247629A1 (fr) | Application d'un fragment oligonucléotidique double brin non homologue dans un système d'inactivation génétique | |
WO2023109887A1 (fr) | Procédé de détection de site d'intégration | |
WO2024078626A1 (fr) | Procédé pour améliorer l'efficacité de l'édition du génome par knock-in médiée par crispr/cas9 | |
EP4041884A1 (fr) | Vecteur d'administration d'acide nucléique comprenant un polynucléotide monocaténaire circulaire | |
Li et al. | Clustered regularly interspaced short palindromic repeats and clustered regularly Interspaced Short Palindromic Repeats–Associated protein 9 system: factors affecting Precision Gene Editing Efficiency and optimization strategies | |
RU2712492C1 (ru) | Средство разрезания днк на основе cas9 белка из defluviimonas sp. | |
RU2712497C1 (ru) | Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum | |
TW202346580A (zh) | Dna酶及其應用 | |
유지현 | Versatile application of the CRISPR-Cas system to various organisms | |
WO2023196476A1 (fr) | Compositions et procédés de complexes arn guide/marqueur de séquençage pour éditeur primaire | |
CN118531031A (zh) | 单链DNA结合蛋白介导的体外CRISPR/Cas9基因编辑方法及其应用 | |
OA20196A (en) | DNA-cutting agent. | |
OA20197A (en) | DNA-cutting agent. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20959559 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20959559 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20959559 Country of ref document: EP Kind code of ref document: A1 |